BISMUTH SUBSALICYLATE SUSPENSION 17.6MG/ML 17.6 MG — DIN 00876526
BISMUTH SUBSALICYLATE : 17.6 MG · STANLEY PHARMACEUTICALS, A DIVISION OF VITA HEALTH PRODUCTS INC. · SUSPENSION · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is BISMUTH SUBSALICYLATE SUSPENSION 17.6MG/ML?
BISMUTH SUBSALICYLATE SUSPENSION 17.6MG/ML 17.6 MG contains BISMUTH SUBSALICYLATE : 17.6 MG. It is listed in the Health Canada Drug Product Database under DIN 00876526, held by STANLEY PHARMACEUTICALS, A DIVISION OF VITA HEALTH PRODUCTS INC., supplied as SUSPENSION for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 31-Jul-2002. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
How much does Bismuth Preparations cost around the world?
Bismuth Preparations is listed on 2 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Greece publishes a producer price (ex-factory); United States publishes a acquisition. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 1 | 2 | USD███.██ |
| Greece | producer price (ex-factory) | 1 | 1 | EUR███.██ |
3 pack listings across 2 brand entries and 2 price bases, refreshed 03 Sep 2026. Ranges span every Bismuth Preparations pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Bismuth Preparations in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
28 holders have a Canadian DIN containing Bismuth Preparations, across 55 DINs, of which 12 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| PROCTER & GAMBLE INC | 8 | 5 | PEPTO BISMOL CAPLET - 262MG/CAPLET, PEPTO BISMOL EXTRA INSTACOOL, PEPTO BISMOL LIQUICAPS, PEPTO-BISMOL, PEPTO-BISMOL CHEWS, +3 more | Sourceable in Canada |
| JUNO OTC INC | 4 | 3 | BISMUTH CAPLETS, BISMUTH CHEWABLES, EXTRA STRENGTH BISMUTH, REGULAR STRENGTH BISMUTH | Sourceable in Canada |
| GUARDIAN DRUG COMPANY INC | 3 | 3 | BISMUTH SUBSALICYLATE CAPLETS, BISMUTH SUBSALICYLATE SUSPENSION, EXTRA STRENGTH BISMUTH SUBSALICYLATE SUSPENSION | Sourceable in Canada |
| CHURCH & DWIGHT CANADA CORP | 1 | 1 | GASTROVOL LIQUID GELS | Sourceable in Canada |
| CELLCHEM PHARMACEUTICALS INC. | 4 | 0 | BISMUTH, BISMUTH SUBSALICYLATE LIQUID EXTRA STRENGTH, BISMUTH SUBSALICYLATE SUSPENSION, BISMUTH SUBSALICYLATE TABLETS | No marketed DIN |
| JAMP PHARMA CORPORATION | 3 | 0 | BISMUTH CAPLETS, BISMUTH CHEWABLES, EXTRA STRENGTH BISMUTH | No marketed DIN |
| PERRIGO INTERNATIONAL | 3 | 0 | BISMUTH, EXTRA-STRENGTH BISMUTH, PINK BISMUTH-LIQ 17.6MG/ML | No marketed DIN |
| TECHNILAB PHARMA INC. | 3 | 0 | BISMED LIQ 17.66MG/ML, BISMUTH LIQ 17.6MG/ML, PINK BISMUTH ROSE LIQ 17.6MG/ML | No marketed DIN |
| TEVA CANADA LIMITED | 3 | 0 | BISMUTH CAPLETS, BISMUTH CHEWABLES, REGULAR STRENGTH BISMUTH | No marketed DIN |
| ARROW OTC COMPANY | 2 | 0 | BISMUTH (CHERRY FLAVOUR), BISMUTH (ORIGINAL FORMULA) | No marketed DIN |
| STANLEY PHARMACEUTICALS, A DIVISION OF VITA HEALTH PRODUCTS INC. | 2 | 0 | BISMUTH SUBSALICYLATE SUSPENSION 17.6MG/ML, BISMYLATE-BISMUTH SUBSALICYLATE SUS 17.6GM/ML | No marketed DIN |
| TANTA PHARMACEUTICALS INC | 2 | 0 | BISMUTH CAPLETS, BISMUTH LIQUID | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 17.6 MG |
|---|---|
| Dosage form | SUSPENSION |
| Route | ORAL |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Bismuth Preparations |
|---|---|
| ATC code | A07BB |
| AHFS class | 56:04.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 00876526 |
|---|---|
| DIN (unpadded, as printed on some documents) | 876526 |
| Brand name | BISMUTH SUBSALICYLATE SUSPENSION 17.6MG/ML |
| Generic / active ingredient | BISMUTH SUBSALICYLATE : 17.6 MG |
| Market authorization holder | STANLEY PHARMACEUTICALS, A DIVISION OF VITA HEALTH PRODUCTS INC. |
| Health Canada schedule | NON-PRESCRIPTION DRUGS |
| ATC code | A07BB |
| ATC anatomical main group | A — Alimentary tract and metabolism |
| ATC therapeutic subgroup | A07BB |
| Current status | CANCELLED POST MARKET |
| Status date | 31-Jul-2002 |
| Original market date | 1992-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
12 of 55 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| BISMUTH CAPLETS | 262 MG | TABLET | JUNO OTC INC | MARKETED | 02457121 |
| BISMUTH SUBSALICYLATE CAPLETS | 262 MG | TABLET | GUARDIAN DRUG COMPANY INC | MARKETED | 02326582 |
| BISMUTH SUBSALICYLATE SUSPENSION | 17.5 MG | SUSPENSION | GUARDIAN DRUG COMPANY INC | MARKETED | 02313162 |
| EXTRA STRENGTH BISMUTH | 35.2 MG | SUSPENSION | JUNO OTC INC | MARKETED | 02475855 |
| EXTRA STRENGTH BISMUTH SUBSALICYLATE SUSPENSION | 35 MG | SUSPENSION | GUARDIAN DRUG COMPANY INC | MARKETED | 02328453 |
| GASTROVOL LIQUID GELS | 262 MG | CAPSULE | CHURCH & DWIGHT CANADA CORP | MARKETED | 02534436 |
| PEPTO BISMOL CAPLET - 262MG/CAPLET | 262 MG | TABLET | PROCTER & GAMBLE INC | MARKETED | 02177994 |
| PEPTO BISMOL LIQUICAPS | 262 MG | CAPSULE | PROCTER & GAMBLE INC | MARKETED | 02499991 |
| PEPTO-BISMOL | 17.6 MG | SUSPENSION | PROCTER & GAMBLE INC | MARKETED | 02097079 |
| PEPTO-BISMOL EXTRA | 35.2 MG | SUSPENSION | PROCTER & GAMBLE INC | MARKETED | 02229668 |
2 · Same class — other molecules in ATC A07BB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Bismuth Preparations | BISMED LIQ 17.66MG/ML · BISMUTH · BISMUTH (CHERRY FLAVOUR) · BISMUTH (ORIGINAL FORMULA) · +35 more | 55 | 12 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC A07B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| A07BA | Charcoal Preparations · Medicinal Charcoal · Medicinal Charcoal, Combinations | 34 | 10 |
| A07BC | Attapulgite · Attapulgite, Combinations · Combinations · Kaolin, Combinations · Pectin, Combinations | 20 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.